The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis

Figure 4. This analysis simultaneously varies all parameters over the full range of plausible values. Each point represents the incremental cost-effectiveness ratio generated by one trial through the simulation. The median incremental cost-effectiveness ratio of $268 000 per quality-adjusted life-year ( ) gained is shown ( ), and, by definition, 50% of the trials fall on either side. Points below and to the right of each line represent trials that generated an incremental cost-effectiveness ratio below the specified threshold. For example, if a third-party payer was willing to pay $150 000 per QALY gained for coxib therapy, then only 4.3% of the patients in this simulation would fall within the budget. WTP = willingness-to-pay thresholds.
Figure 4. This analysis simultaneously varies all parameters over the full range of plausible values. Each point represents the incremental cost-effectiveness ratio generated by one trial through the simulation. The median incremental cost-effectiveness ratio of $268 000 per quality-adjusted life-year ( ) gained is shown ( ), and, by definition, 50% of the trials fall on either side. Points below and to the right of each line represent trials that generated an incremental cost-effectiveness ratio below the specified threshold. For example, if a third-party payer was willing to pay $150 000 per QALY gained for coxib therapy, then only 4.3% of the patients in this simulation would fall within the budget. WTP = willingness-to-pay thresholds. Probabilistic sensitivity analysis using 1000 trials.QALYsolid line

This Article

  1. Ann Intern Med May 20, 2003 vol. 138 no. 10 795-806
  1. AbstractFREE
  2. Figures
  3. Full Text
  4. Full Text (PDF)

Current Issue

  1. November 17, 2009, 151 (10)
  1. Alert me to current issues